Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2010

View Archived Issues

GNE-A shows preclinical potential as anticancer agent

Ensemble Therapeutics describes Ensemblins

Bristol-Myers Squibb generates backup IGF-I receptor inhibitor to BMS-754807 for cancer

Cara Therapeutics' CR-09 shows promise in preclinical study

YM-150 is safe and tolerated in phase II trial in nonvalvular atrial fibrillation

Presidio Pharma claims new HCV NS5A inhibitors

Bristol-Myers Squibb presents new HCV NS5A inhibitors

Novo Nordisk reviews progress of first half of 2010

Promising phase Ib/IIa data on OBP-601 in HIV

Bachem and Atheris collaborate on Melusine peptide toxin libraries

Genmab and Seattle Genetics to collaborate on antibody-drug conjugates

Biotie reports on phase I study of BTT-1023 in plaque psoriasis

NeuroSearch claims new activators of voltage-gated K(V)7 potassium channels

Cel-Sci to initiate enrollment in phase III trial of Multikine in head and neck cancer

Mimetica presents new modulators of melanocortin receptors

Almirall and Ironwood Pharma report phase III data on linaclotide in IBS-C

Almirall describes new inhibitors of DPDE4

Diamyd to outlicense NP-2 following phase II trial in cancer

Cell Therapeutics to appeal FDA decision on NDA for pixantrone in NHL

Capstone presents update on trials of AZX-100 in keloid scarring

FDA approves phase III trial of INCB-18424 in polycythemia vera

GenVec achieves milestone in collaboration with Novartis

Number of U.K. sites for international OvPlex study increases

AMRI moves IBS candidate into advanced preclinical testing

Eisai reports on Japanese trials of SEP-190 in insomnia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...